This bill (A 786) clarifies court procedures for temporarily detaining defendants who violate pretrial release conditions or commit new crimes while on release. It requires courts to find "clear and convincing evidence" that no bail or conditions would ensure court appearance or public safety before revoking release, and mandates consideration of risk assessments for new offenses. The bill specifically prevents revocation for marijuana-related violations (e.g., possession under N.J.S.2C:35-10 or 2C:35-5). It directly affects defendants on pretrial release who face new charges or breach release terms, ensuring consistent application of existing standards. The changes align with a 2023 criminal justice reform recommendation.
This bill requires the New Jersey Supreme Court to automatically dismiss unresolved municipal court charges, complaints, and arrest warrants for specific low-level offenses that have remained pending for five years or longer. It applies to offenses like shoplifting under $200, minor assault, disorderly conduct, and possession of small amounts of marijuana (50g or less), but excludes violations of municipal ordinances. The bill also mandates that the state's Administrative Office of the Courts conduct two studies within six months: one on expanding existing dismissal programs and another on implementing a voluntary surrender program for non-violent offenses. These provisions aim to reduce court backlogs and eliminate outdated legal actions against individuals.
Bill S 3340 allows New Jersey counties to establish specialized "central municipal drug courts" to handle drug-related cases. Counties that choose to create such courts would manage cases referred by county health departments, police, or the court system, focusing specifically on drug offenses within their jurisdiction. The bill requires counties to pass an ordinance and file it with the Administrative Director of the Courts to create these courts. This provides an optional framework for counties to develop dedicated court resources for drug-related matters, without mandating any county to implement it.
This bill increases penalties for manufacturing, distributing, or dispensing certain Schedule I and II controlled substances in New Jersey. It raises the severity of offenses based on drug quantity - for example, heroin or cocaine analogs in 5 ounces or more become a first-degree crime (with mandatory minimum prison time), while smaller amounts face lower-degree charges. Key changes include stricter sentencing ranges (requiring one-third to one-half of the sentence to be served without parole eligibility) and higher fines, up to $500,000 for first-degree offenses. The bill directly affects individuals involved in distributing these drugs, including heroin, methamphetamine, LSD, PCP, and marijuana (with specific quantity thresholds for marijuana offenses).
This bill increases penalties for crimes involving heroin and fentanyl, resulting in longer prison sentences for offenders. It establishes new criminal offenses for specific heroin mixtures (blends containing heroin combined with other substances) and expands eligibility for drug court programs. Defendants charged with these offenses may now qualify for drug court, which provides treatment-focused alternatives to incarceration. These changes apply to individuals in New Jersey facing drug-related charges under state law.
This bill requires drivers involved in motor vehicle accidents that result in death to submit to an evaluation by a certified drug recognition expert (a law enforcement officer trained to identify drug impairment). It directly affects drivers involved in fatal crashes who refuse such evaluations. Key provisions include: refusing the evaluation leads to license restrictions (requiring an ignition interlock device for first offenses, up to 8 years for third offenses), fines ($300-$1,000 depending on offense count), and mandatory referral to an Intoxicated Driver Resource Center. The law amends existing statutes to expand testing requirements beyond alcohol to include drugs, with penalties increasing for repeat refusals.
This law makes it a crime to sell or possess parts designed to convert standard firearms into machine guns (known as "machine gun conversion devices"). It directly affects sellers and owners of these specific firearm components. The bill establishes criminal penalties for violating this prohibition, adding to existing firearm regulations. The law was enacted after being approved in P.L.2025, c.363, and is now part of New Jersey state law.
This bill removes criminal liability for New Jersey law enforcement officers who interact with underage individuals regarding alcohol or cannabis possession, unless the officer intentionally discriminates based on race, gender, religion, or other protected characteristics. Currently, officers face criminal charges for such encounters regardless of intent, but this bill changes that by requiring proof of discriminatory purpose to trigger liability. Key provisions clarify that officers cannot be charged for routine actions like issuing warnings or conducting stops without reasonable suspicion - unless they act with discriminatory intent. The change directly affects officers responding to underage possession calls and the young people involved in these encounters.
This bill creates a new criminal offense for marketing fentanyl in ways specifically designed to appeal to minors, targeting manufacturers, distributors, or sellers. It prohibits tactics like packaging resembling candy, food, or popular characters, using minor-targeted advertising, or violating FDA/DEA packaging rules. Violators face a minimum 30-year prison sentence with no parole eligibility, and prior fentanyl distribution convictions create a strong presumption of guilt. The law directly affects businesses or individuals distributing fentanyl with marketing strategies targeting youth, aiming to deter such practices through severe penalties.
This New Jersey bill (A 864) classifies xylazine - a sedative often misused in illicit drug mixtures - as a Schedule III controlled substance under state law, except when used by veterinarians for animal treatment. Schedule III means it has accepted medical use but potential for abuse leading to moderate dependence, subjecting unauthorized use to criminal penalties. Specifically, illegal possession, distribution, or use of xylazine would be a third-degree crime, punishable by 3-5 years in prison and fines up to $35,000, with enhanced penalties near schools or for distributing to minors. The bill directly affects individuals misusing xylazine (including in human drug use) and law enforcement, while exempting veterinary medical use.
